Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Current Topics in Microbiology and Immunology|June 22, 2010
Modulation of CTLA-4 and GITR for cancer immunotherapyFrancesca Avogadri, Jianda Yuan, Arvin Yang, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic functionMythili Koneru, David Schaer, Ngozi Monu, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 4, 2006
Defective adhesion in tumor infiltrating CD8+ T cellsMythili Koneru, Ngozi Monu, David Schaer, et al.Oncoimmunology|September 14, 2016
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapyRikke B Holmgaard, Alexandra Brachfeld, Billel Gasmi, et al.The Journal of Clinical Investigation|June 15, 2011
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanomaMiriam Benezra, Oula Penate-Medina, Pat B Zanzonico, et al.Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.Molecular Imaging and Biology|June 18, 2021
Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging TherapyKevin P Maresca, Jianqing Chen, Divya Mathur, et al.Plos One|April 5, 2018
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibodyRandi B Gombos, Ana Gonzalez, Mariana Manrique, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2020
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I StudyKaren A Autio, Christopher A Klebanoff, David Schaer, et al.Pageof 1